打开APP

百时美施贵宝与Syngene签署5年扩展协议

  1. Biocon
  2. Syngene
  3. 百时美施贵宝
  4. 药物发现

来源:生物谷 2014-06-04 09:00

百时美施贵宝与Syngene及印度百康(Biocon)签署5年扩展协议,推进双方合作中已产生的6个化合物至临床试验。自2007年以来,双方已在百康-百时美研究中心开展合作。

2014年6月4日讯 /生物谷BIOON/ --百时美施贵宝(BMS)和印度最大的合同研究组织Syngene国际6月3日联合宣布,双方已就在印度的药物发现和开发合作签署了一项5年扩展协议。

自2007年以来,百时美一直与Syngene及其母公司印度百康(Biocon)在百时美位于印度班加罗尔的百康-百时美研究中心(BBRC),合作开发在医药和工艺化学、生物学、生物技术、生物标记、药物代谢和药代动力学、分析研究及药物开发方面的综合能力。

该合作已产生了6种候选药物用于进一步研究,同时也帮助百时美缩短了将新化合物推进至临床试验的时间并降低了成本。其中一个候选药物目前已处于多个临床试验。此次协议的财务条款尚未披露。(生物谷Bioon.com)

英文原文:Bristol-Myers Squibb and Syngene International Extend Research Collaboration

PRINCETON, N.J. & BANGALORE, India--(BUSINESS WIRE)--Bristol-Myers Squibb (NYSE:BMY) and Syngene International, India’s largest contract research organization, today announced a five-year extension of their drug discovery and development collaboration in India. Financial terms were not disclosed.

Since 2007, Bristol-Myers Squibb has been working with Syngene and its corporate parent, Biocon Ltd., to develop integrated capabilities in medicinal and process chemistry, biology, biotechnology, biomarkers, drug metabolism and pharmacokinetics, analytical research, and pharmaceutical development at the Biocon Bristol-Myers Squibb Research Center (BBRC) in Bangalore.

The U.S.-India collaboration has produced six drug candidates for further study and also helped Bristol-Myers Squibb reduce the time and costs associated with advancing new compounds to first-in-human studies. One drug candidate currently in clinical trials was discovered at BBRC and early nonclinical development work done at BBRC has enabled most of Bristol-Myers Squibb’s small molecule assets to advance to later stages of development over the last five years.

Commenting on the new agreement, Peter Bains, director, Syngene International, said: “We are extremely delighted to extend our discovery and development partnership with Bristol-Myers Squibb for another five years. This extension reflects the strength of our existing collaboration which has delivered many successful outcomes. The scope of Syngene’s engagement has expanded to encompass a broad range of integrated service offerings across the drug discovery and development continuum. We remain committed to supporting Bristol-Myers Squibb in their pursuit of developing new and innovative medicines for the future.”

Francis Cuss, executive vice president and chief scientific officer, Bristol-Myers Squibb, said: “I am excited about the opportunity to continue our highly productive collaboration with Biocon and Syngene. The BBRC has supported the nonclinical development of a large proportion of our small-molecule portfolio assets since its inception, and is a premier example of the high-quality innovative drug hunting that is taking place in India today.”

Bristol-Myers Squibb and Syngene jointly developed the BBRC at Biocon Park in Bangalore. Over the years, BBRC has become Bristol-Myers Squibb’s largest research and development center outside the United States, housing more than 400 scientists.

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->